(AMGN) Amgen - Overview
Sector: HealthcareIndustry: Drug Manufacturers - General | Exchange NASDAQ (USA) | Currency USD | Market Cap: 190.792m | Total Return 19.2% in 12m
Stock: Biologics, Treatments, Therapies, Medicines
Total Rating 69
Risk 59
Buy Signal 0.36
| Risk 5d forecast | |
|---|---|
| Volatility | 26.8% |
| Relative Tail Risk | -11.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.60 |
| Alpha | 10.86 |
| Character TTM | |
|---|---|
| Beta | 0.393 |
| Beta Downside | 0.709 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.74% |
| CAGR/Max DD | 0.76 |
EPS (Earnings per Share)
Revenue
Description: AMGN Amgen March 05, 2026
Amgen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics globally. The biotechnology sector is characterized by high research and development costs and long product development cycles.
Amgens product portfolio addresses various conditions, including rheumatoid arthritis, plaque psoriasis, osteoporosis, and cancer. Key products include Enbrel, Otezla, Prolia, XGEVA, and Repatha. The companys business model involves direct sales to healthcare providers and distribution through pharmaceutical wholesale networks.
Amgen also engages in collaboration agreements with other pharmaceutical companies for product development and commercialization, a common strategy in the industry to share risk and leverage expertise. Further analysis of Amgens product pipeline and market share can be found on ValueRay.
Headlines to watch out for
- Patent expirations on key drugs erode revenue
- New drug approvals drive future growth
- Biosimilar competition impacts established product sales
- Collaboration agreements expand pipeline and market reach
- Regulatory scrutiny on drug pricing affects profitability
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 7.71b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -2.38 > 1.0 |
| NWC/Revenue: 9.70% < 20% (prev 17.74%; Δ -8.04% < -1%) |
| CFO/TA 0.11 > 3% & CFO 9.96b > Net Income 7.71b |
| Net Debt (45.48b) to EBITDA (18.69b): 2.43 < 3 |
| Current Ratio: 1.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (543.0m) vs 12m ago 0.18% < -2% |
| Gross Margin: 70.49% > 18% (prev 0.62%; Δ 6.99k% > 0.5%) |
| Asset Turnover: 40.31% > 50% (prev 36.39%; Δ 3.92% > 0%) |
| Interest Coverage Ratio: 4.88 > 6 (EBITDA TTM 18.69b / Interest Expense TTM 2.77b) |
Altman Z'' 0.14
| A: 0.04 (Total Current Assets 29.06b - Total Current Liabilities 25.49b) / Total Assets 90.59b |
| B: -0.28 (Retained Earnings -25.11b / Total Assets 90.59b) |
| C: 0.15 (EBIT TTM 13.52b / Avg Total Assets 91.21b) |
| D: -0.20 (Book Value of Equity -16.45b / Total Liabilities 81.93b) |
| Altman-Z'' Score: 0.14 = B |
Beneish M -2.98
| DSRI: 1.16 (Receivables 9.57b/7.50b, Revenue 36.77b/33.42b) |
| GMI: 0.87 (GM 70.49% / 61.53%) |
| AQI: 0.97 (AQ_t 0.59 / AQ_t-1 0.61) |
| SGI: 1.10 (Revenue 36.77b / 33.42b) |
| TATA: -0.02 (NI 7.71b - CFO 9.96b) / TA 90.59b) |
| Beneish M-Score: -2.98 (Cap -4..+1) = A |
What is the price of AMGN shares?
As of March 27, 2026, the stock is trading at USD 353.16 with a total of 2,044,564 shares traded.
Over the past week, the price has changed by +0.93%, over one month by -6.90%, over three months by +6.81% and over the past year by +19.15%.
Over the past week, the price has changed by +0.93%, over one month by -6.90%, over three months by +6.81% and over the past year by +19.15%.
Is AMGN a buy, sell or hold?
Amgen has received a consensus analysts rating of 3.63.
Therefor, it is recommend to hold AMGN.
- StrongBuy: 10
- Buy: 5
- Hold: 14
- Sell: 1
- StrongSell: 2
What are the forecasts/targets for the AMGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 350.6 | -0.7% |
| Analysts Target Price | 350.6 | -0.7% |
AMGN Fundamental Data Overview March 27, 2026
P/E Trailing = 24.8721
P/E Forward = 15.8479
P/S = 5.1915
P/B = 21.6549
P/EG = 2.3302
Revenue TTM = 36.77b USD
EBIT TTM = 13.52b USD
EBITDA TTM = 18.69b USD
Long Term Debt = 50.01b USD (from longTermDebt, last quarter)
Short Term Debt = 4.60b USD (from shortTermDebt, last quarter)
Debt = 54.60b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 45.48b USD (from netDebt column, last quarter)
Enterprise Value = 236.27b USD (190.79b + Debt 54.60b - CCE 9.13b)
Interest Coverage Ratio = 4.88 (Ebit TTM 13.52b / Interest Expense TTM 2.77b)
EV/FCF = 29.17x (Enterprise Value 236.27b / FCF TTM 8.10b)
FCF Yield = 3.43% (FCF TTM 8.10b / Enterprise Value 236.27b)
FCF Margin = 22.03% (FCF TTM 8.10b / Revenue TTM 36.77b)
Net Margin = 20.97% (Net Income TTM 7.71b / Revenue TTM 36.77b)
Gross Margin = 70.49% ((Revenue TTM 36.77b - Cost of Revenue TTM 10.85b) / Revenue TTM)
Gross Margin QoQ = 81.91% (prev 67.75%)
Tobins Q-Ratio = 2.61 (Enterprise Value 236.27b / Total Assets 90.59b)
Interest Expense / Debt = 1.20% (Interest Expense 653.0m / Debt 54.60b)
Taxrate = 11.96% (181.0m / 1.51b)
NOPAT = 11.90b (EBIT 13.52b * (1 - 11.96%))
Current Ratio = 1.14 (Total Current Assets 29.06b / Total Current Liabilities 25.49b)
Debt / Equity = 6.31 (Debt 54.60b / totalStockholderEquity, last quarter 8.66b)
Debt / EBITDA = 2.43 (Net Debt 45.48b / EBITDA 18.69b)
Debt / FCF = 5.61 (Net Debt 45.48b / FCF TTM 8.10b)
Total Stockholder Equity = 7.98b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.45% (Net Income 7.71b / Total Assets 90.59b)
RoE = 96.65% (Net Income TTM 7.71b / Total Stockholder Equity 7.98b)
RoCE = 23.32% (EBIT 13.52b / Capital Employed (Equity 7.98b + L.T.Debt 50.01b))
RoIC = 18.70% (NOPAT 11.90b / Invested Capital 63.67b)
WACC = 5.96% (E(190.79b)/V(245.40b) * Re(7.37%) + D(54.60b)/V(245.40b) * Rd(1.20%) * (1-Tc(0.12)))
Discount Rate = 7.37% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 0.28%
[DCF] Terminal Value 86.57% ; FCFF base≈9.02b ; Y1≈9.23b ; Y5≈10.27b
[DCF] Fair Price = 480.3 (EV 304.37b - Net Debt 45.48b = Equity 258.89b / Shares 539.1m; r=6.0% [WACC]; 5y FCF grow 2.27% → 3.0% )
EPS Correlation: 68.71 | EPS CAGR: 6.01% | SUE: 1.92 | # QB: 6
Revenue Correlation: 93.81 | Revenue CAGR: 13.10% | SUE: 2.01 | # QB: 3
EPS next Quarter (2026-06-30): EPS=5.85 | Chg7d=+0.001 | Chg30d=+0.020 | Revisions Net=+2 | Analysts=24
EPS current Year (2026-12-31): EPS=22.38 | Chg7d=-0.005 | Chg30d=+0.010 | Revisions Net=-1 | Growth EPS=+2.5% | Growth Revenue=+2.9%
EPS next Year (2027-12-31): EPS=23.28 | Chg7d=+0.002 | Chg30d=+0.025 | Revisions Net=+1 | Growth EPS=+4.0% | Growth Revenue=+2.5%
[Analyst] Revisions Ratio: +0.50 (3 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.9% (Discount Rate 7.9% - Earnings Yield 4.0%)
[Growth] Growth Spread = -0.4% (Analyst 3.5% - Implied 3.9%)
P/E Forward = 15.8479
P/S = 5.1915
P/B = 21.6549
P/EG = 2.3302
Revenue TTM = 36.77b USD
EBIT TTM = 13.52b USD
EBITDA TTM = 18.69b USD
Long Term Debt = 50.01b USD (from longTermDebt, last quarter)
Short Term Debt = 4.60b USD (from shortTermDebt, last quarter)
Debt = 54.60b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 45.48b USD (from netDebt column, last quarter)
Enterprise Value = 236.27b USD (190.79b + Debt 54.60b - CCE 9.13b)
Interest Coverage Ratio = 4.88 (Ebit TTM 13.52b / Interest Expense TTM 2.77b)
EV/FCF = 29.17x (Enterprise Value 236.27b / FCF TTM 8.10b)
FCF Yield = 3.43% (FCF TTM 8.10b / Enterprise Value 236.27b)
FCF Margin = 22.03% (FCF TTM 8.10b / Revenue TTM 36.77b)
Net Margin = 20.97% (Net Income TTM 7.71b / Revenue TTM 36.77b)
Gross Margin = 70.49% ((Revenue TTM 36.77b - Cost of Revenue TTM 10.85b) / Revenue TTM)
Gross Margin QoQ = 81.91% (prev 67.75%)
Tobins Q-Ratio = 2.61 (Enterprise Value 236.27b / Total Assets 90.59b)
Interest Expense / Debt = 1.20% (Interest Expense 653.0m / Debt 54.60b)
Taxrate = 11.96% (181.0m / 1.51b)
NOPAT = 11.90b (EBIT 13.52b * (1 - 11.96%))
Current Ratio = 1.14 (Total Current Assets 29.06b / Total Current Liabilities 25.49b)
Debt / Equity = 6.31 (Debt 54.60b / totalStockholderEquity, last quarter 8.66b)
Debt / EBITDA = 2.43 (Net Debt 45.48b / EBITDA 18.69b)
Debt / FCF = 5.61 (Net Debt 45.48b / FCF TTM 8.10b)
Total Stockholder Equity = 7.98b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.45% (Net Income 7.71b / Total Assets 90.59b)
RoE = 96.65% (Net Income TTM 7.71b / Total Stockholder Equity 7.98b)
RoCE = 23.32% (EBIT 13.52b / Capital Employed (Equity 7.98b + L.T.Debt 50.01b))
RoIC = 18.70% (NOPAT 11.90b / Invested Capital 63.67b)
WACC = 5.96% (E(190.79b)/V(245.40b) * Re(7.37%) + D(54.60b)/V(245.40b) * Rd(1.20%) * (1-Tc(0.12)))
Discount Rate = 7.37% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 0.28%
[DCF] Terminal Value 86.57% ; FCFF base≈9.02b ; Y1≈9.23b ; Y5≈10.27b
[DCF] Fair Price = 480.3 (EV 304.37b - Net Debt 45.48b = Equity 258.89b / Shares 539.1m; r=6.0% [WACC]; 5y FCF grow 2.27% → 3.0% )
EPS Correlation: 68.71 | EPS CAGR: 6.01% | SUE: 1.92 | # QB: 6
Revenue Correlation: 93.81 | Revenue CAGR: 13.10% | SUE: 2.01 | # QB: 3
EPS next Quarter (2026-06-30): EPS=5.85 | Chg7d=+0.001 | Chg30d=+0.020 | Revisions Net=+2 | Analysts=24
EPS current Year (2026-12-31): EPS=22.38 | Chg7d=-0.005 | Chg30d=+0.010 | Revisions Net=-1 | Growth EPS=+2.5% | Growth Revenue=+2.9%
EPS next Year (2027-12-31): EPS=23.28 | Chg7d=+0.002 | Chg30d=+0.025 | Revisions Net=+1 | Growth EPS=+4.0% | Growth Revenue=+2.5%
[Analyst] Revisions Ratio: +0.50 (3 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.9% (Discount Rate 7.9% - Earnings Yield 4.0%)
[Growth] Growth Spread = -0.4% (Analyst 3.5% - Implied 3.9%)